HLB Therapeutics Co.,Ltd.
115450
Classement en actions
#18267
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Prix de l'action
$2.02
Capitalisation boursière
$190.66M
Changement (1 jour)
7.96%
Changement (1 an)
-1.16%
Pays
KR
Échange HLB Therapeutics Co.,Ltd. (115450)
Catégorie
Healthcare
Ratio P/B pour HLB Therapeutics Co.,Ltd. (115450)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de HLB Therapeutics Co.,Ltd., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour HLB Therapeutics Co.,Ltd. de 2026 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
